Information Provided By:
Fly News Breaks for May 16, 2018
BMRN
May 16, 2018 | 07:21 EDT
Canaccord analyst Michelle Gilson initiated BioMarin with a Buy rating as she likes the setup heading into 2019. The analyst sees current risk levels skewed toward negative outcomes around its Pegvaliase PDUFA and hemophilia A gene therapy competitor data. She believes the gene therapy platform may be underappreciated. Gilson has a $101 price target on BioMarin shares.
News For BMRN From the Last 2 Days
There are no results for your query BMRN